PriceTargets.com logo

Rapt Therapeutics - RAPT Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $50.50
  • Forecasted Upside: 46.50%
  • Number of Analysts: 11
  • Breakdown:
  • 1 Sell Ratings
  • 2 Hold Ratings
  • 6 Buy Ratings
  • 2 Strong Buy Ratings
$34.47 As of 12/4/2025 05:00 PM ET
▲ +2.38 (7.42%)

This chart shows the closing price for RAPT by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Rapt Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for RAPT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for RAPT

Analyst Price Target is $50.50
▲ +46.50% Upside Potential
This price target is based on 11 analysts offering 12 month price targets for Rapt Therapeutics in the last 3 months. The average price target is $50.50, with a high forecast of $72.00 and a low forecast of $9.00. The average price target represents a 46.50% upside from the last price of $34.47.

This chart shows the closing price for RAPT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 11 investment analysts is to moderate buy stock in Rapt Therapeutics. This rating has held steady since July 2025, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 9 hold ratings
  • 0 sell ratings
Ratings as of
6/12/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 9 hold ratings
  • 0 sell ratings
Ratings as of
9/10/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 10 hold ratings
  • 1 sell ratings
Ratings as of
12/9/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 6 hold ratings
  • 1 sell ratings
Ratings as of
3/9/2025
  • 1 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
6/7/2025
  • 1 strong buy ratings
  • 2 buy ratings
  • 5 hold ratings
  • 0 sell ratings
Ratings as of
9/5/2025
  • 2 strong buy ratings
  • 6 buy ratings
  • 4 hold ratings
  • 1 sell ratings
Ratings as of
11/4/2025
  • 2 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
12/4/2025

Latest Recommendations

  • 2 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/12/2025JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$55.00 ➝ $57.00
11/7/2025BarclaysLower TargetOverweight ➝ Overweight$58.00 ➝ $56.00
11/3/2025Wells Fargo & CompanySet TargetOverweight ➝ Overweight$48.00 ➝ $72.00
10/27/2025HC WainwrightBoost TargetBuy ➝ Buy$27.00 ➝ $72.00
10/27/2025GuggenheimInitiated CoverageNeutral ➝ Buy$70.00
10/21/2025Wells Fargo & CompanyReiterated RatingOverweight ➝ Overweight$38.00 ➝ $48.00
10/21/2025BarclaysBoost TargetOverweight ➝ Overweight$35.00 ➝ $58.00
10/20/2025JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$13.00 ➝ $55.00
10/13/2025BarclaysSet TargetEqual Weight ➝ Overweight$35.00
10/13/2025BarclaysInitiated CoverageEqual Weight ➝ Overweight$35.00
10/8/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/27/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/26/2025Leerink PartnersUpgradeMarket Perform ➝ Outperform$16.00 ➝ $37.00
9/25/2025Leerink PartnrsUpgradeHold ➝ Strong-Buy
8/22/2025Zacks ResearchDowngradeStrong-Buy ➝ Hold
8/12/2025UBS GroupSet TargetNeutral ➝ Neutral$8.00 ➝ $9.00
8/8/2025Wells Fargo & CompanyReiterated RatingOverweight ➝ Overweight$51.00 ➝ $38.00
7/30/2025JPMorgan Chase & Co.UpgradeUnderweight ➝ Neutral$14.00
7/22/2025Lifesci CapitalUpgradeStrong-Buy$31.00
7/10/2025HC WainwrightBoost TargetBuy ➝ Buy$27.00
5/22/2025UBS GroupLower TargetNeutral ➝ Neutral$16.00 ➝ $8.00
5/22/2025HC WainwrightUpgradeStrong-Buy$48.00
3/10/2025HC WainwrightReiterated RatingBuy ➝ Buy$80.00 ➝ $80.00
12/26/2024HC WainwrightUpgradeNeutral ➝ Buy$80.00 ➝ $80.00
11/25/2024HC WainwrightReiterated RatingNeutral
11/13/2024Stifel NicolausReiterated RatingBuy ➝ Hold$56.00 ➝ $16.00
11/12/2024Wells Fargo & CompanyLower TargetOverweight ➝ Overweight$136.00 ➝ $32.00
11/12/2024HC WainwrightReiterated RatingNeutral
11/11/2024Piper SandlerDowngradeOverweight ➝ Neutral$64.00 ➝ $16.00
11/11/2024JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight
9/9/2024UBS GroupLower TargetNeutral ➝ Neutral$80.00 ➝ $16.00
8/20/2024HC WainwrightReiterated RatingNeutral
7/23/2024HC WainwrightReiterated RatingNeutral
5/14/2024Wolfe ResearchReiterated RatingOutperform ➝ Peer Perform
5/10/2024GuggenheimDowngradeBuy ➝ Neutral
5/10/2024BarclaysDowngradeOverweight ➝ Equal Weight$104.00 ➝ $32.00
4/10/2024HC WainwrightReiterated RatingNeutral
3/27/2024JPMorgan Chase & Co.Lower TargetNeutral ➝ Neutral$120.00 ➝ $104.00
2/22/2024UBS GroupDowngradeBuy ➝ Neutral$488.00 ➝ $80.00
2/21/2024Leerink PartnrsDowngradeOutperform ➝ Market Perform
2/21/2024BarclaysLower TargetOverweight ➝ Overweight$280.00 ➝ $104.00
2/21/2024Leerink PartnersDowngradeOutperform ➝ Market Perform$336.00 ➝ $80.00
2/21/2024JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$280.00 ➝ $120.00
2/21/2024HC WainwrightDowngradeBuy ➝ Neutral
2/20/2024Cantor FitzgeraldDowngradeOverweight ➝ Neutral
2/16/2024Evercore ISIInitiated CoverageOutperform
2/15/2024Wolfe ResearchInitiated CoverageOutperform$312.00
11/30/2023JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$256.00 ➝ $280.00
11/15/2023HC WainwrightReiterated RatingBuy ➝ Buy$328.00
9/14/2023Berenberg BankInitiated CoverageBuy$272.00
8/16/2023JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$312.00 ➝ $256.00
8/14/2023HC WainwrightReiterated RatingBuy ➝ Buy$328.00
8/14/2023Piper SandlerBoost TargetOverweight ➝ Overweight$224.00 ➝ $248.00
8/8/2023Stifel NicolausInitiated CoverageBuy$320.00
6/15/2023BarclaysInitiated CoverageOverweight$280.00
5/12/2023HC WainwrightLower Target$344.00 ➝ $328.00
3/30/2023HC WainwrightReiterated RatingBuy$344.00
3/21/2023JPMorgan Chase & Co.Lower TargetOverweight$384.00 ➝ $336.00
3/21/2023HC WainwrightReiterated RatingBuy$344.00
3/15/2023The Goldman Sachs GroupLower TargetBuy$216.00 ➝ $184.00
3/15/2023GuggenheimLower TargetBuy$440.00 ➝ $384.00
3/15/2023Cantor FitzgeraldLower Target$352.00 ➝ $320.00
3/15/2023HC WainwrightLower TargetBuy$400.00 ➝ $344.00
1/4/2023Wells Fargo & CompanyLower TargetOverweight$440.00 ➝ $384.00
1/4/2023GuggenheimInitiated CoverageBuy$440.00
12/8/2022Piper SandlerLower Target$272.00 ➝ $264.00
12/1/2022The Goldman Sachs GroupInitiated CoverageBuy$216.00
11/14/2022HC WainwrightLower TargetBuy$424.00 ➝ $400.00
11/10/2022Piper SandlerBoost TargetOverweight$240.00 ➝ $272.00
9/21/2022Capital One FinancialInitiated CoverageOverweight$384.00
8/12/2022HC WainwrightBoost TargetBuy$400.00 ➝ $424.00
8/11/2022Leerink PartnersLower TargetOutperform$392.00 ➝ $384.00
6/23/2022HC WainwrightLower TargetBuy$448.00 ➝ $400.00
5/12/2022Piper SandlerLower Target$416.00 ➝ $240.00
4/1/2022Cantor FitzgeraldReiterated RatingOverweight
3/16/2022Roth CapitalReiterated RatingBuy
3/14/2022HC WainwrightReiterated RatingBuy$448.00
3/11/2022Piper SandlerLower TargetOverweight$488.00 ➝ $416.00
3/11/2022Wells Fargo & CompanyLower TargetOverweight$520.00 ➝ $440.00
12/9/2021JPMorgan Chase & Co.Initiated CoverageOverweight$488.00
11/16/2021Cantor FitzgeraldLower TargetOverweight$568.00 ➝ $464.00
10/4/2021Leerink PartnersReiterated RatingBuy
8/30/2021HC WainwrightReiterated RatingBuy$448.00
8/12/2021Leerink PartnersInitiated CoverageOutperform$392.00
6/23/2021HC WainwrightBoost TargetBuy$232.00 ➝ $448.00
6/20/2021Piper SandlerInitiated CoverageOverweight$488.00
6/14/2021Wells Fargo & CompanyBoost TargetOverweight$240.00 ➝ $520.00
6/14/2021Roth CapitalBoost TargetPositive ➝ Buy$304.00 ➝ $576.00
6/14/2021Cantor FitzgeraldBoost TargetOverweight$408.00 ➝ $568.00
5/26/2021Cantor FitzgeraldReiterated RatingOverweight
5/17/2021HC WainwrightLower TargetBuy$256.00 ➝ $232.00
3/12/2021HC WainwrightBoost TargetBuy$240.00 ➝ $256.00
(Data available from 12/4/2020 forward)

News Sentiment Rating

0.63 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 7 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
5/8/2025
  • 8 very positive mentions
  • 5 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
6/7/2025
  • 4 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
7/7/2025
  • 5 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/6/2025
  • 1 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/5/2025
  • 5 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/5/2025
  • 8 very positive mentions
  • 30 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
11/4/2025
  • 8 very positive mentions
  • 8 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
12/4/2025

Current Sentiment

  • 8 very positive mentions
  • 8 positive mentions
  • 2 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Rapt Therapeutics logo
RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. RAPT Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb Company
Read More

Today's Range

Now: $34.47
Low: $31.72
High: $34.73

50 Day Range

MA: $29.43
Low: $25.00
High: $34.47

52 Week Range

Now: $34.47
Low: $5.67
High: $42.39

Volume

441,066 shs

Average Volume

387,480 shs

Market Capitalization

$955.16 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.43

Frequently Asked Questions

What sell-side analysts currently cover shares of Rapt Therapeutics?

The following equities research analysts have issued research reports on Rapt Therapeutics in the last twelve months: Barclays PLC, Guggenheim, HC Wainwright, JPMorgan Chase & Co., Leerink Partners, Leerink Partnrs, Lifesci Capital, UBS Group AG, Wall Street Zen, Weiss Ratings, Wells Fargo & Company, and Zacks Research.
View the latest analyst ratings for RAPT.

What is the current price target for Rapt Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Rapt Therapeutics in the last year. Their average twelve-month price target is $50.50, suggesting a possible upside of 46.0%. Wells Fargo & Company has the highest price target set, predicting RAPT will reach $72.00 in the next twelve months. UBS Group AG has the lowest price target set, forecasting a price of $9.00 for Rapt Therapeutics in the next year.
View the latest price targets for RAPT.

What is the current consensus analyst rating for Rapt Therapeutics?

Rapt Therapeutics currently has 1 sell rating, 2 hold ratings, 6 buy ratings and 2 strong buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for RAPT.

What other companies compete with Rapt Therapeutics?

Other companies that are similar to Rapt Therapeutics include CG Oncology, Disc Medicine, Mineralys Therapeutics, Tarsus Pharmaceuticals and Telix Pharmaceuticals. Learn More about companies similar to Rapt Therapeutics.

How do I contact Rapt Therapeutics' investor relations team?

Rapt Therapeutics' physical mailing address is 561 ECCLES AVENUE, SOUTH SAN FRANCISCO CA, 94080. The company's listed phone number is (650) 489-9000 and its investor relations email address is [email protected]. The official website for Rapt Therapeutics is www.rapt.com. Learn More about contacing Rapt Therapeutics investor relations.